Arvinas, Inc. (ARVN) and Pfizer Inc. (PFE) Thursday announced positive 6-month follow up data from a Phase 1b study evaluating vepdegestrant in combination with Pfizer's breast cancer drug Palbociclib in heavily pre-treated breast cancer patients.
The Phase 1b study was designed to assess the safety, tolerability, and anti-tumor activity of vepdegestrant in combination with palbociclib in patients with heavily pre-treated breast cancer. Initial positive data were presented at San Antonio Breast Cancer Symposium (SABCS) in December 2023.
After six months of additional follow-up, the combination therapy could achieve clinical benefit rate of 63%, overall response rate of 41.9%, and median progression-free survival of 11.2 months. Additionally, safety profile of vepdegestrant in combination with palbociclib was consistent with data previously reported at SABCS in December last year.
Vepdegestrant, co-developed by Arvinas and Pfizer, is being evaluated as a monotherapy in the ongoing Phase 3 VERITAC-2 trial and in combination with palbociclib in the ongoing Phase 3 VERITAC-3 trial in patients with breast cancer.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.